Literature DB >> 18264760

Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.

Ben Van Calster1, Isabelle Vanden Bempt, Maria Drijkoningen, Nathalie Pochet, Jiqiu Cheng, Sabine Van Huffel, Wouter Hendrickx, Julie Decock, Huei-Jean Huang, Karin Leunen, Frederic Amant, Patrick Berteloot, Robert Paridaens, Hans Wildiers, Erik Van Limbergen, Caroline Weltens, Dirk Timmerman, Toon Van Gorp, Ann Smeets, Walter Van den Bogaert, Ignace Vergote, Marie-Rose Christiaens, Patrick Neven.   

Abstract

AIMS: To examine the frequency of axillary lymph node (ALN) invasion of operable breast cancers by their combined oestrogen receptor (ER), progesterone receptor (PR) and HER-2 status.
METHODS: 2227 recently operated cases in one centre were retrieved from the Multidisciplinary Breast Centre database and stratified according to their combined immunohistochemical (IHC) expression of ER/PR/HER-2 status. An equivocal HER-2 status was further analysed by Fluorescence in situ Hybridisation (FISH). The following 6 groups were considered: ER(-)PR(-)HER-2(-) (NNN; triple negative), ER(-)PR(-)HER-2(+) (NNP), ER(+)PR(-)HER-2(-) (PNN), ER(+)PR(-)HER-2(+) (PNP), ER(+)PR(+)HER-2(- )(PPN), ER(+)PR(+)HER-2(+) (PPP; triple positive). For ALN, the following variables were tested in uni- and multivariate models: age at diagnosis (years), tumour size (mm), tumour grade, ER, PR, HER-2 and the combined steroid receptor and HER-2 status. Likelihood ratio chi(2)-tests were used for univariate analysis and logistic regression for multivariate analysis.
RESULTS: Triple positive tumours had a higher likelihood of being ALN positive than others (56.2% versus 35.7%; P<0.0001). Univariate logistic regression also withheld age, size, grade and HER-2 as predictors of ALN involvement. Final multivariate logistic regression revealed age, size, grade and PPP versus non-PPP to be independent predictors of ALN involvement; the odds ratio (OR) and 95% CI for PPP versus non-PPP tumours was 2.169 (1.490-3.156).
CONCLUSION: Our data provide insight into the natural history of triple positive breast carcinomas. Such tumours are more likely ALN positive than those with another steroid receptor and HER-2 status. How these findings correlate with breast cancer prognosis remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18264760     DOI: 10.1007/s10549-008-9914-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

1.  Association between molecular subtypes and lymph node status in invasive breast cancer.

Authors:  Chengshuai Si; Yiting Jin; Hongying Wang; Qiang Zou
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  N-acetylglucosaminyl 1-phosphate transferase: an excellent target for developing new generation breast cancer therapeutic.

Authors:  Aditi Banerjee; Juan A Martinez; Maria O Longas; Zhenbo Zhang; Jesus Santiago; Krishna Baksi; Dipak K Banerjee
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

3.  Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer.

Authors:  Nilufer Bulut; Sercan Aksoy; Omer Dizdar; Didem S Dede; Cagatay Arslan; Erkan Dogan; Ibrahim Gullu; Yavuz Ozisik; Kadri Altundag
Journal:  Med Oncol       Date:  2010-10-21       Impact factor: 3.064

4.  Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer.

Authors:  Nicholas K Howland; Teryn D Driver; Michael P Sedrak; Xianfeng Wen; Wenli Dong; Sandra Hatch; Mahmoud A Eltorky; Celia Chao
Journal:  J Surg Res       Date:  2013-07-11       Impact factor: 2.192

5.  Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer.

Authors:  Hikmat Abdel-Razeq; Sara Edaily; Sereen Iweir; Mourad Salam; Yacob Saleh; Maher Sughayer; Osama Salama; Rawan Mustafa; Yosra Al-Masri; Rayan Bater; Ayat Taqash
Journal:  Breast Cancer Res Treat       Date:  2020-09-24       Impact factor: 4.872

6.  Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?

Authors:  Tiffanie Jones; Hanmanth Neboori; H Wu; Qifeng Yang; Bruce G Haffty; Susan Evans; Susan Higgins; Meena S Moran
Journal:  Ann Surg Oncol       Date:  2013-05-10       Impact factor: 5.344

7.  Triple-negative breast cancer and obesity in a rural Appalachian population.

Authors:  Linda Vona-Davis; David P Rose; Hannah Hazard; Marissa Howard-McNatt; Farrell Adkins; Jessica Partin; Gerald Hobbs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

8.  Study on the skip metastasis of axillary lymph nodes in breast cancer and their relation with Gli1 expression.

Authors:  Huan Wang; Xiao-Yun Mao; Ting-Ting Zhao; Xin-Yu Zheng; Feng Jin; Ji-Guang Li
Journal:  Tumour Biol       Date:  2012-07-14

9.  Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification.

Authors:  Fabien Reyal; Catherine Belichard; Roman Rouzier; Emmanuel de Gournay; Claire Senechal; Francois-Clement Bidard; Jean-Yves Pierga; Paul Cottu; Florence Lerebours; Youlia Kirova; Jean-Guillaume Feron; Virginie Fourchotte; Anne Vincent-Salomon; Jean-Marc Guinebretiere; Brigitte Sigal-Zafrani; Xavier Sastre-Garau; Yann De Rycke; Charles Coutant
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

10.  The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma.

Authors:  Fabien Reyal; Roman Rouzier; Berenice Depont-Hazelzet; Marc A Bollet; Jean-Yves Pierga; Severine Alran; Remy J Salmon; Virginie Fourchotte; Anne Vincent-Salomon; Xavier Sastre-Garau; Martine Antoine; Serge Uzan; Brigitte Sigal-Zafrani; Yann De Rycke
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.